Wronski SL, Mordin M, Kelley K, Anguiano RH, Classi P, Shen E, Manaker S. The role of noninvasive endpoints in predicting long-term outcomes in pulmonary arterial hypertension. Lung. 2020 Feb;198(1):65-86. doi: 10.1007/s00408-019-00289-2
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe F, Pifarre J, Alseda M, Ortega M. Overview of the impact of depression and anxiety in chronic obstructive pulmonary disease. Lung. 2017 Feb;195(1):77-85. doi: 10.1007/s00408-016-9966-0
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Bernfort L, Brodtkorb T. QALY som effektmått inom vården : möjligheter och begränsningar. Linköping: linköping University Electronic Press. Cmt- Rapport. 2012.
Mangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Research. 2011 Feb 1;4(1):9-12.
Lash TL, Johansen MB, Christensen S, Baron JA, Rothman KJ, Hansen JG, Sorensen HT. Hospitalization rates and survival associated with COPD: a nationwide Danish cohort study. Lung. 2011 Feb 1;189(1):27-35.
Brodtkorb T. National system for assessment, prioritization and introduction of non-pharmaceutical health technologies, a pilot study. Cmt- Rapport. 2010.